REFERENCES
- Ludwig H, Fritz E. Overview of clinical trials on rHuEPO in cancer patients. In: Bokemeyer C, Ludwig H, eds. Anaemia in cancer, ESO Scientific Updates, Vol 6. 1st ed. Amsterdam: Elsevier Science B.V. 2001. p. 115–43.
- Olsson A-M, Svensson J-H, Sundström J, et al. Erythropoietin treatment in metastatic breast cancer: effects on Hb, quality of life and need for transfusion. Acta Oncol 2002; 41: 517–24.
- Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of EPOetin Alfa on hematologic para-meters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74.
- Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglo-bin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carci-noma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705–15.
- Silver DF, Piver MS. Effects of recombinant human erythro-poietin on the antitumour effect of Cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999; 73: 280–4.
- Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459–60.
- Henke M, Laszig R, Rale C, Schafer U, et al. Erythropoietin to treat head and neck cancer patients with anaemia under-going radiotherapy: randomised, double-blind, placebo-controlled study. Lancet 2003; 362: 1255–60.
- Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561–5.
- Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021–9.
- Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58: 647–57.
- Caro JJ, Salas M, Ward A, Goss G. Anaemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91: 2214–21.
- Vaupel P, Mayer A, Briest S, Höckel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003; 63: 7634–7.
- Hockel M, Vaupel P. Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266–76.
- Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nature Rev Cancer 2002; 2: 38–47.
- Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139–68.
- Helczynska K, Kronblad A, Jogi A, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003; 63: 1441–4.
- Kronblad A, Helczynska K, Nielsen NH, Emdin S, Nhlman S, Landberg G. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer. In vivo 2003; 17: 311 —8.
- Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci 2002; 99: 7021–6.